The crystal study:: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri

被引：0
|
作者：
Van Cutsem, E. [1 ]
Lang, I [2 ]
D'haens, G. [3 ]
Moiseyenko, V [4 ]
Zaluski, J. [5 ]
Koehne, C. [6 ]
Folprecht, G. [7 ]
Tejpar, S. [1 ]
Shparyk, Y. [8 ]
Schlichting, M. [9 ]
Kisker, O. [9 ]
Stroh, C. [9 ]
Rougier, P. [10 ]
机构：
[1] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[2] Orszagos Onkol Intezet, Budapest, Hungary
[3] Imelda Ziekenhuis, Bonheiden, Belgium
[4] NN Petrov Oncol Res Inst, St Petersburg, Russia
[5] Weikopolskie Centrum Onkol, Poznan, Poland
[6] Klinikum Oldenburg, Oldenburg, Germany
[7] Univ Klin Carl Gustav Carus, Dresden, Germany
[8] Lviv Oncol Med & Diagnost Ctr, Lvov, Ukraine
[9] Merck Serono, Darmstadt, Germany
[10] Hop Ambroise Pare, Boulogne, France
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [1] FOLFIRI plus cetuximab—preferred first-line treatment for mCRC
    Lisa Hutchinson
    Nature Reviews Clinical Oncology, 2014, 11 (10) : 560 - 560
  • [2] First-line therapy with cetuximab followed by cetuximab plus folfiri in patients with metastatic colorectal cancer: KRAS mutation status correlates with clinical outcome
    Martinelli, E.
    Macarulia, T.
    Vega-Villegas, E.
    Rodriguez-Braun, E.
    Ciardiello, F.
    Ramos, F.
    Rivera, F.
    Stroh, C.
    Nippgen, J.
    Cervantes, A.
    Baselga, J.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 25 - 25
  • [3] KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience
    Van Cutsem, E.
    Lang, I.
    D'haens, G.
    Moiseyenko, V.
    Zaluski, J.
    Folprecht, G.
    Tejpar, S.
    Kisker, O.
    Stroh, C.
    Rougier, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): New results from the CRYSTAL trial
    Ciardiello, Fortunato
    Lenz, Heinz-Josef
    Kohne, Claus-Henning
    Heinemann, Volker
    Tejpar, Sabine
    Esser, Regina
    Beier, Frank
    Stroh, Christopher
    Duecker, Klaus
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [5] KRAS STATUS AND EFFICACY IN THE CRYSTAL STUDY: 1ST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) RECEIVING FOLFIRI WITH OR WITHOUT CETUXIMAB
    Van Cutsem, Eric
    Lang, Istvan
    D'Haens, Geerts
    Moiseyenko, Vladimir
    Zaluski, Jerzy
    Folprecht, Gunnar
    Tejpar, Sabine
    Nippgen, Johannes
    Stroh, Christopher
    Rougier, Philippe
    ANNALS OF ONCOLOGY, 2008, 19 : 4 - 4
  • [6] KRAS STATUS AND EFFICACY IN THE CRYSTAL STUDY: 1ST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) RECEIVING FOLFIRI WITH OR WITHOUT CETUXIMAB
    Van Cutsem, E.
    Lang, I.
    D'Haens, G.
    Moiseyenko, V.
    Zaluski, J.
    Folprecht, G.
    Tejpar, S.
    Nippgen, J.
    Stroh, C.
    Rougier, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 44 - 45
  • [7] RELATIONSHIP BETWEEN KRAS STATUS AND EFFICACY OF FOLFOX6+CETUXIMAB OR FOLFIRI plus CETUXIMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): THE CECOG/CORE1.2.001 TRIAL
    Ocvirk, J.
    Vrbanec, D.
    Beslija, S.
    Koza, I
    Ciuleanu, T.
    Papamichael, D.
    Wrba, F.
    Messinger, D.
    Zielinski, C.
    Brodowicz, T.
    ANNALS OF ONCOLOGY, 2009, 20 : 17 - 17
  • [8] Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC)
    Cervantes, A.
    Macarulla, T.
    Martinelli, E.
    Rodriguez-Braun, E.
    Ciardiello, F.
    Stroh, C.
    Nippgen, J.
    Baselga, J.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Cetuximab plus folfiri first-line in metastatic colorectal cancer (MCRC): The randomized phase III crystal trial
    Koehne, C.
    Zaluski, J.
    Chung, Rong C.
    Makhson, A.
    D'Haens, G.
    Pinter, T.
    Lim, R.
    Ruff, P.
    Rougier, P.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2007, 18 : VII21 - VII21
  • [10] Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6+cetuximab (FX plus C) or FOLFIRI plus cetuximab (FF plus C): The CECOG/CORE1.2.001 trial
    Koza, I., Sr.
    Wrba, F.
    Vrbanec, D.
    Ocvirk, J.
    Ciuleanu, T. E.
    Beslija, S.
    Papamichael, D.
    Messinger, D.
    Zielinski, C. C.
    Brodowicz, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345